Article
Activation of the AKT/mTOR pathway in autosomal recessive polycystic kidney disease (ARPKD).
Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association - 1 Jun 2009
Fischer Dagmar-Christiane, Jacoby Ulrike, Pape Lars, Ward Christopher J, Kuwertz-Broeking Eberhard, Renken Catharina, Nizze Horst, Querfeld Uwe, Rudolph Birgit, Mueller-Wiefel Dirk E, Bergmann Carsten, Haffner Dieter
Abstract excerpt
BACKGROUND: Autosomal recessive polycystic kidney disease (ARPKD) [MIM 263200] belongs to a group of congenital hepatorenal fibrocystic syndromes and is caused by mutations in the PKHD1 gene encoding the multidomain protein fibrocystin/polyductin (FPC). The serine-threonine kinase mammalian target of rapamycin (mTOR) is one of the most important gate-keepers integrating numerous signals related to cell...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.